Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Operating Leases: 2019-2024

Historic Operating Leases for Fortress Biotech (FBIO) over the last 6 years, with Dec 2024 value amounting to $14.8 million.

  • Fortress Biotech's Operating Leases fell 16.52% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year decrease of 16.52%. This contributed to the annual value of $14.8 million for FY2024, which is 19.32% down from last year.
  • Latest data reveals that Fortress Biotech reported Operating Leases of $14.8 million as of FY2024, which was down 19.32% from $18.3 million recorded in FY2023.
  • Fortress Biotech's Operating Leases' 5-year high stood at $23.1 million during FY2020, with a 5-year trough of $14.8 million in FY2024.
  • Its 3-year average for Operating Leases is $18.2 million, with a median of $18.3 million in 2023.
  • Per our database at Business Quant, Fortress Biotech's Operating Leases climbed by 2.79% in 2022 and then declined by 19.32% in 2024.
  • Over the past 5 years, Fortress Biotech's Operating Leases (Yearly) stood at $23.1 million in 2020, then decreased by 9.15% to $21.0 million in 2021, then increased by 2.79% to $21.6 million in 2022, then dropped by 15.25% to $18.3 million in 2023, then declined by 19.32% to $14.8 million in 2024.